866-997-4948(US-Canada Toll Free)

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 91 Pages

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2016, provides in depth analysis on Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted pipeline therapeutics.

The report provides comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Overview 9
Therapeutics Development 10
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Stage of Development 10
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Therapy Area 11
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Indication 12
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Companies 15
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Products under Development by Universities/Institutes 18
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development 26
AC Immune SA 26
AFFiRiS AG 27
BioArctic Neuroscience AB 28
Biogen Inc 29
Genmab A/S 30
Neuropore Therapies Inc 31
nLife Therapeutics SL 32
Primary Peptides, Inc. 33
Proclara Biosciences Inc 34
Prothena Corp Plc 35
QR Pharma Inc 36
reMYND NV 37
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles 38
ABL-301 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
AV-1947D - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
AV-1948D - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
AV-1949D - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
AV-1950D - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
AV-1950R - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
BAN-0805 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
BIIB-054 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
CLR-01 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
DPC-003 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Kenterin - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Monoclonal Antibody to Inhibit Alpha-Synuclein for Parkinsons Disease - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
NLFPD-1233 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
NPT-088 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
NPT-20011 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
NPT-289 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
NPT-3G - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
NPT100-18A - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
PD-01 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
PD-03 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
PD-04 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Posiphen - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
PP-003 - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
PRX-002 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
quinpramine - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
ReS-12S - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
ReS-9S - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
trehalose - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Vaccine to Target Alpha-Synuclein for Parkinson's Disease - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Projects 79
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Featured News & Press Releases 81
Nov 18, 2016: Proclara Biosciences Awarded Part the Cloud Grant from Alzheimers Association to Support Development of NPT088 for Alzheimers Disease 81
Nov 16, 2016: Proclara Biosciences Announces Newly Issued U.S. Patents for its Core Technology Targeting Protein Misfolding Disorders 81
Nov 09, 2016: Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease 82
Sep 07, 2016: Proclara Biosciences Announces Initiation of Phase 1b Clinical Trial of NPT088 for Alzheimers Disease 83
Mar 22, 2016: Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11 83
Aug 12, 2015: Neuropore Therapies Commences Phase 1 Clinical Trials 84
Jul 19, 2015: NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference 84
Jul 13, 2015: NeuroPhage to be Featured in Oral Session at the 2015 Alzheimers Association International Conference 85
Jul 02, 2015: BIIB054 reached significant milestone 85
Jun 17, 2015: Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease 85
Jun 15, 2015: BioArctic Neuroscience Parkinsons disease program receives grant from VINNOVA 86
Jun 08, 2015: Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders 87
Apr 02, 2015: 2nd US patent granted on therapeutic antibodies for Parkinsons disease 87
Mar 19, 2015: Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease 87
Mar 16, 2015: NeuroPhage to Present at 12th International Conference on Alzheimers & Parkinsons Diseases 89
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 90
Disclaimer 91

List of Tables
Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Pipeline by AC Immune SA, H2 2016 26
Pipeline by AFFiRiS AG, H2 2016 27
Pipeline by BioArctic Neuroscience AB, H2 2016 28
Pipeline by Biogen Inc, H2 2016 29
Pipeline by Genmab A/S, H2 2016 30
Pipeline by Neuropore Therapies Inc, H2 2016 31
Pipeline by nLife Therapeutics SL, H2 2016 32
Pipeline by Primary Peptides, Inc., H2 2016 33
Pipeline by Proclara Biosciences Inc, H2 2016 34
Pipeline by Prothena Corp Plc, H2 2016 35
Pipeline by QR Pharma Inc, H2 2016 36
Pipeline by reMYND NV, H2 2016 37
Dormant Projects, H2 2016 79
Dormant Projects (Contd..1), H2 2016 80

List of Figures
Number of Products under Development for, H2 2016 10
Number of Products under Development by Therapy Area, H2 2016 11
Number of Products under Development by Top 10 Indication, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Actions, H2 2016 21
Number of Products by Routes of Administration, H2 2016 22
Number of Products by Stage and Routes of Administration, H2 2016 22
Number of Products by Molecule Types, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *